SCHEMBL4282201

SCHEMBL4282201

O=C(O)N1CCN(C(=O)O)[C@H](CCNc2ccccc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAN1B1 Q9UKM7 1/20 0.38
DPP4 P27487 1/20 0.38
EPHX1 P07099 1/20 0.36
YAP1 P46937 1/20 0.36
TEAD4 Q15561 1/20 0.36
FAAH O00519 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA1 P00915 6/20 0.35
CA2 P00918 6/20 0.35
CA4 P22748 6/20 0.35
CA9 Q16790 6/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
AGTR2 P50052 1/20 0.35
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292964 0.86 MAPT (0.45) NPSR1MAPTALDH1A1NPC1RAB9A
SCHEMBL4287930 0.85 F10 (0.38) MAPTGAAALOX15ALOX12MAPK1
SCHEMBL4295533 0.85 ATM (0.43) MAPTALDH1A1NPC1TP53RAB9A
SCHEMBL4283875 0.83 MEN1 (0.42) MAPTALDH1A1GAA
SCHEMBL4286525 0.79 RAB9A (0.47) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4292160 0.79 MAOA (0.47) MAPTALDH1A1GAA
SCHEMBL4284653 0.79 PRMT3 (0.44) NPSR1MAPTALDH1A1NPC1GAA
SCHEMBL4293573 0.78 SMN1; SMN2 (0.37) ALDH1A1RAB9ASMN1; SMN2GAAMAPK1
SCHEMBL4285411 0.77 ROCK2 (0.46)
SCHEMBL4281174 0.76 ALDH1A1 (0.46) MAPTALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT MAN1B1 3224/4885DPP4 113/4885EPHX1 747/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT MAN1B1 3224/4885DPP4 113/4885EPHX1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.